Marketed in 36 countries across Europe, Latin America, the Asia-Pacific region, and parts of the Middle East, Isoptin is an internationally distributed brand of verapamil hydrochloride, classified within the cardiovascular agent category with antihypertensive, antianginal, and antiarrhythmic roles. For travellers and expatriates already familiar with the brand, the page below collates the markets where Isoptin is registered and the indications recognised by national regulators.
Verapamil hydrochloride is prescribed in the management of hypertension and in certain cardiac rhythm disorders, including paroxysmal supraventricular tachycardia and other tachyarrhythmias. The structured indication list further down this page details each registered use as recognised in the markets where Isoptin is sold, and is the primary reference for what the brand is formally authorised to address.
Because Isoptin has a wide international footprint, it is frequently encountered abroad — sometimes as Isoptin itself, sometimes as a verapamil-containing generic under a different commercial name. Markets where the brand is registered include Germany, Egypt, Australia, Colombia, and Hong Kong, but regulatory packaging, prescription requirements, and available formulations vary considerably between these jurisdictions. A pharmacist in the destination country is usually the right first point of contact for confirming whether a locally available verapamil product corresponds to the one a patient has been using at home.
Other medications in the broader cardiovascular category are sold across the same markets under different molecules and brand names, although they are not freely interchangeable with verapamil. Substitution between cardiovascular agents — even within an apparently similar role — is a clinical decision, and any change to ongoing therapy should be made together with a healthcare provider who knows the patient's history.
